Keywords: Contrast Agents, Brain, glioma
Motivation: Neurological adverse effects caused by the deposition of gadolinium-based contrast agents in the brain remain uncertain, and it is necessary to develop a biocompatible alternative molecule for evaluation of glioma malignancy and site occupancy.
Goal(s): To demonstrate that Fe-based contrast agents have superior safety, stability, and longevity in glioma imaging compared to gadolinium-based contrast agents.
Approach: The T7-Fe-PyC3A was synthesized, and its stability was validated through in vitro kinetic thermodynamic experiments. Furthermore, A in situ glioma model mice was choosen for investigating the imaging ability.
Results: A targeted Fe-based MR contrast agent provides clear glioma contours with a 15-60 minutes post-dose imaging window.
Impact: Although gadolinium-based contrast agents are widely used in the clinic, iron-based contrast agents targeting gliomas show the enhanced safety and stability profile. The extended imaging window allows them as preferable alternative for gliomas imaging.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords